Search

Objective: To investigate the clinical effect of phloroglucin combined with labetalol in the treatment of pregnancy induced hypertension and its possible mechanisms. Methods: 180 cases of patients with hypertensive disorder complicating pregnancy who were treated in our hospital from December 2015 to December 2018, according to the order of admission, the random number table method is divided into two groups with 9 cases in each group. The control group was given phloroglucinol 200 mg intravenously for 7 days. The observation group was combined with intravenous drip of 100 mg of labetalol. When the patient's blood pressure dropped to the target period, the administration method was changed to oral labetalol tablets, 50 mg each time, three times a day, until before delivery. The outcomes of delivery (placental abruption, postpartum hemorrhage, fetal distress, cesarean section, low birth weight infants and neonatal asphyxia) and the changes of ystolic blood pressure (SBP), mean arterial pressure (MAP), diastolic blood pressure (DBP), serum cysteine protease inhibitor C (Cys-C), high mobility protein-1 (HMGB1) and homocysteine (Hcy) levels before and after treatment were compared between the two groups. Results: After treatment, the total effective rate of observation group (92.22%) was significantly higher than that of the control group (74.44%, P<0.05). The rates of placental abruption, postpartum hemorrhage, fetal distress, cesarean section, low birth weight and neonatal asphyxia in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the SBP, MAP and DBP of both groups were significantly decreased (P<0.05), which were more obvious decreased in the observation group (P<0.05). The levels of SBP, MAP and DBP, serum Hcy, HMGB1 and Cys-C in the two groups were significantly lower than those before treatment (P<0.05), and the above indicators in the observation group were significantly lower than the control group (P<0.05). Conclusion: The combination of phloroglucin and labetalol can significantly reduce the incidence of adverse delivery outcomes in pregnancy-induced hypertension and control blood pressure. The mechanism may be related to the reduction of serum Hcy, HMGB1 and Cys-C levels. [ABSTRACT FROM AUTHOR]

To study the clinical effect and possible mechanism of vitamin E combined with nimodipine in the treatment of pregnancy-induced hypertension syndrome. 200 patients with pregnancy-induced hypertension syndrome who were treated in our hospital from January 2016 to December 2018 were randomly divided into two groups. The control group was given oral vitamin E treatment, 50 mg each time, three times a day, the observation group was treated with oral nimodipine, 30 mg each time, twice a day. The changes of serum copeptin, cortisol, NO and endothelin, CRP, IL-12 and TNF-琢levels before and after treatment were detected and compared between the two groups. And the pregnancy outcome: placental abruption, postpartum hemorrhage, fetal distress, cesarean section, low birth weight and neonatal asphyxia were recorded. After treatment, the total effective rate of observation group was significantly higher than that of the control group (91% vs. 73%, P<0.05). After treatment, the levels of serum peptide, cortisol and endothelin in the two groups were significantly lower than those of the control group, while the levels of serum nitric oxide were significantly higher, and the above indicators in the observation group were significantly better than those of the control group (both P< 0.05). After treatment, the levels of serum CRP, IL-12 and TNF-琢in the two groups were significantly decreased, and the the above indexes in the observation group were significantly lower than those in the control group (all P<0.05). The rates of placental abruption, postpartum hemorrhage, fetal distress, cesarean section, low birth weight and neonatal asphyxia in the observation group were significantly lower than those in the control group (P<0.05). Vitamin E combined with nimodipine can significantly improve the pregnancy outcome of hypertensive syndrome in pregnancy, it may be related to the decrease of serum CRP, IL-12 and TNF-琢, cortisol, peptide, and levels. [ABSTRACT FROM AUTHOR]